--- canonical_url: https://www.stockexpertai.com/earnings/unh last_updated: 2026-05-03T20:47:27.596Z --- # UnitedHealth Group Incorporated (UNH) Q1 FY2027 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-03T20:47:26.413Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $368.78 (▼ -0.46%) | fmp:quote | | Market Cap | $334.7B | fmp:profile | | 52w range | $234.60 – $409.70 | fmp:quote | | Earnings | Tue 4 Aug | fmp:earnings-history | | EPS estimate | $4.83 (+18% YoY) | fmp:earnings-estimate | | Revenue estimate | $110.7B | fmp:earnings-estimate | | Beat streak | 3/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $380 (+3.0% upside) | fmp:price-target-consensus | | MoonshotScore | 40/100 | derived | | Council | 3/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## UnitedHealth Group Incorporated — Q1 FY2027 Expectations Q1 consensus: revenue $110.7B^{[FMP est]}, EPS $4.83^{[FMP est]}. 3 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** HOLD · **Council:** 3/6 · **Moonshot:** 40 = MoonshotScore 40^{[9-pillar formula]} + Council 3/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (6 metrics) ### 1. Optum Health Margin Improvement Optum Health is focused on steadily improving margins for 2026 and accelerating into 2027. > "As we have shared over the past 3 quarters, our efforts are focused on management and process improvements that steadily improve margins at Optum Health for 2026 and accelerate into 2027." > — Patrick Conway, Risk Indicator · Q1 FY2026 ### 2. Medicaid Margin Outlook UnitedHealthcare expects membership attrition and negative margins in Medicaid in 2026 due to continuing high trend and insufficient funding, with modest margin improvements beginning in 2027. > "We continue to expect membership attrition and negative margins in 2026 in light of continuing high trend and insufficient funding with modest margin improvements beginning in 2027." > — Timothy Noel, Expectation / Guide · Q1 FY2026 ### 3. Margin Recovery Focus UnitedHealthcare is prioritizing margin recovery and product stability in 2026, with a deliberate trade-off on membership growth, particularly in Medicare and commercial markets. > "Our 2026 approach prioritizes margin recovery and product stability with a deliberate trade-off on membership growth, particularly in Medicare and commercial markets." > — Timothy Noel, Risk Indicator · Q1 FY2026 ### 4. Ai Driven Efficiency Optum Insight Optum Insight's new AI-first products continue to gain traction, with Optum Real helping payers and care providers deal more efficiently with administrative functions such as claim adjudication and coverage validation and can reduce manual contact costs by 76%. > "Optum Real is helping payers and care providers deal more efficiently with administrative functions such as claim adjudication and coverage validation and can reduce manual contact costs by 76%." > — Patrick Conway, Investor Focus · Q1 FY2026 ### 5. Prior Authorization Improvements UnitedHealthcare is working to improve prior authorization processes, with about 50% of requests now processed in real time, and more than 90% approved on average in 1 business day. > "About 50% of those are processed in real time, and more than 90% are approved on average in 1 business day." > — Timothy Noel, Investor Focus · Q1 FY2026 ### 6. Aca Membership Decline UnitedHealthcare still expects total membership to decline by approximately 1/3 in 2026. > "We still expect total membership to decline by approximately 1/3 in 2026." > — Timothy Noel, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth slowing (+0.1%, below threshold) | | Gross Margin | 2.0 | weak | Q1: low margin (22.7%, capital-intensive or commodity) | | Operating Leverage | 1.0 | weak | op margin average (8.0%) | | Cash Runway | 10.0 | strong | FCF very strong ($8.1B, 10.7× CapEx) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 4.0 | medium | RSI 82.7 overbought, 50d above | | News Sentiment | 8.0 | strong | strong buy consensus (82%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +3.0% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | bear | quant · RSI 83 | | Klarman | neutral | value · target upside +3.0% | | Buffett | bull | quality · ROE score 4/5 | | Munger | neutral | valuation · target upside +3.0% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Weak - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 82.7 — overbought (RSI 82.7) — geri çekilme baskısı - **50d MA:** $301 — hisse %22.4 üstünde — kısa vadeli destek - **200d MA:** $315 — hisse %16.9 üstünde — uzun vadeli destek - **Volume (10d):** -51% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $4.08 | $4.45 | MISS | +1.9% | | Q3 FY25 | $2.92 | $2.80 | BEAT | -3.4% | | Q4 FY25 | $2.11 | $2.10 | BEAT | +4.0% | | Q1 FY26 | $7.23 | $6.58 | +9.9% EPS | +2.2% | Q1 (April 21, 2026): EPS $7.23 vs $6.58 est^[FMP], +9.9% beat. D+1 movement: +2.2%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q1 EPS > $4.83 + CapEx discipline** Threshold: EPS > $4.83^{[FMP est]}. Target: Break above median target $380^{[FMP target]}; high target $444^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $4.83 + CapEx < $763.0M** Threshold: EPS ≈ $4.83^{[FMP est]}, Q1 CapEx < $763.0M^[FMP]. Target: Consolidation in the band between current $369^[FMP] and median $380^[FMP]. ### Scenario C · Miss **EPS < $4.69 or CapEx ≥ $763.0M** Threshold: EPS < $4.69^{[FMP est×0.97]}. Target: Current $369 below SMA200 $315^[FMP], if rejection continues, $268^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $7.23 vs $6.58 beat^[FMP], stock +2.2% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $763.0M^{[FMP cashflow]}. Q1 op margin 8.0%^{[FMP op margin]} — this level in Q1 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $380 (+3.0% upside vs current $369) - **High / Low:** $444 / $327 - **Buy / Hold / Sell:** 23 / 4 / 1 - **Analyst count:** 2 (last quarter), 104 all-time ## Additional Transcript Insights ### 1. margin_recovery_focus **Claim:** UnitedHealthcare is prioritizing margin recovery and product stability in 2026, with a deliberate trade-off on membership growth, particularly in Medicare and commercial markets. **Evidence (transcript):** "Our 2026 approach prioritizes margin recovery and product stability with a deliberate trade-off on membership growth, particularly in Medicare and commercial markets." **Numbers:** 2026 ### 2. medicaid_margin_outlook **Claim:** UnitedHealthcare expects membership attrition and negative margins in Medicaid in 2026 due to continuing high trend and insufficient funding, with modest margin improvements beginning in 2027. **Evidence (transcript):** "We continue to expect membership attrition and negative margins in 2026 in light of continuing high trend and insufficient funding with modest margin improvements beginning in 2027." **Numbers:** 2026, 2027 ### 3. aca_membership_decline **Claim:** UnitedHealthcare still expects total membership to decline by approximately 1/3 in 2026. **Evidence (transcript):** "We still expect total membership to decline by approximately 1/3 in 2026." **Numbers:** 1/3, 2026 ### 4. prior_authorization_improvements **Claim:** UnitedHealthcare is working to improve prior authorization processes, with about 50% of requests now processed in real time, and more than 90% approved on average in 1 business day. **Evidence (transcript):** "About 50% of those are processed in real time, and more than 90% are approved on average in 1 business day." **Numbers:** 50%, 90%, 1 ### 5. optum_health_margin_improvement **Claim:** Optum Health is focused on steadily improving margins for 2026 and accelerating into 2027. **Evidence (transcript):** "As we have shared over the past 3 quarters, our efforts are focused on management and process improvements that steadily improve margins at Optum Health for 2026 and accelerate into 2027." **Numbers:** 3, 2026, 2027 ### 6. ai_driven_efficiency_optum_insight **Claim:** Optum Insight's new AI-first products continue to gain traction, with Optum Real helping payers and care providers deal more efficiently with administrative functions such as claim adjudication and coverage validation and can reduce manual contact costs by 76%. **Evidence (transcript):** "Optum Real is helping payers and care providers deal more efficiently with administrative functions such as claim adjudication and coverage validation and can reduce manual contact costs by 76%." **Numbers:** 76% --- *Data source: FMP (live query, 2026-05-03), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*